在线粒体GPX4上GRP78结合位点的计算表征:针对三阴性乳腺癌中向铁亡的含义
Donia G Youssef1,2, Abdo A Elfiky3
1Department of Biophysics, Faculty of Sciences, Cairo University, Giza, 12613, Egypt.
Scientific reports
|January 10, 2026
概括
研究人员探索了GRP78和mGPX4在三阴性乳腺癌 (TNBC) 中的相互作用. 准这种相互作用可能会使攻击性TNBC细胞对铁亡产生敏感,从而提供一种新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 计算生物学 计算生物学
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种具有有限治疗选择的侵袭性亚型.
- 铁和应激反应途径与TNBC进展有关.
- 葡萄糖调节蛋白78 (GRP78) 和线粒体谷氨过氧化酶4 (mGPX4) 分别是应激反应和铁灭症耐药性的关键参与者.
研究的目的:
- 在TNBC的背景下调查GRP78和mGPX4之间的相互作用.
- 用计算方法确定GRP78和mGPX4之间的特定结合区域和亲和关系.
- 评估针对GRP78-mGPX4相互作用作为TNBC治疗策略的潜力.
主要方法:
- 蛋白质与蛋白质对接 (PRODIGY,HADDOCK) 以预测结合点和亲和关系.
- 分子动力学 (MD) 模拟来分析100个nS的复杂稳定性.
- MM/GBSA自由能量计算,以量化结合的自由能量,并确定关键相互作用力.
主要成果:
- 在GRP78的SBDβ域和mGPX4.4的多个区域之间确定了稳定的复合体.
- PRODIGY对接显示出强大的结合亲和力,III区域显示出最高的 (-10.5 ± 0.6 kcal/mol).
- MD模拟和MM/GBSA分析表明,II区域复合物具有最高的结合亲和力 (-86.4 kcal/mol),由静电和范德瓦尔斯力驱动.
结论:
- GRP78-mGPX4相互作用是一个稳定的复合体,具有显著的结合亲和力.
- 这种相互作用为TNBC提供了潜在的治疗点.
- 针对这种相互作用可以使TNBC细胞对铁亡敏感,提供一种新的治疗方法.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129